A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2

Devi, Kasi Pandima; Pourkarim, Mahmoud Reza; Thijssen, Marijn; Sureda, Antoni; Khayatkashani, Maryam; Cismaru, Cosmin Andrei; Berindan‐Neagoe, Ioana; Habtemariam, Solomon; Razmjouei, Soha; Kashani, Hamid Reza Khayat

doi:10.1007/s43440-021-00344-x

Cited by 20 publications

(15 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several compounds with potency inhibit human furin, e.g., decanoyl-Arg-Val-Lys-Arg-chloromethylketone, α1-antitrypsin Portland or succinoyl esters of andrographolide isolated from the herbaceous plant Andrographis paniculate (Burm.f.) Nees [ 74 ]. As evidenced, furin inhibitor decanoyl-RVKR-CMK has been demonstrated to inhibit the processing of SARS-CoV-2 successfully.…”

Section: Pharmaceutical Targets Of Sars-cov-2mentioning

confidence: 99%

Oral antiviral treatments for COVID-19: opportunities and challenges

Rahmah

Arero²,

Jibril³

et al. 2022

Pharmacol. Rep

View full text Add to dashboard Cite

The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication and prevent disease progression to a more severe form. However, the timing of antiviral treatment plays a crucial role in this regard. Oral antiviral drugs provide an opportunity to manage SARS-CoV-2 infection without a need for hospital admission, easing the general burden that COVID-19 can have on the healthcare system. This review paper (i) presents the potential pharmaceutical antiviral targets, including various host-based targets and viral-based targets, (ii) characterizes the first-generation anti-SARS-CoV-2 oral drugs (nirmatrelvir/ritonavir and molnupiravir), (iii) summarizes the clinical progress of other oral antivirals for use in COVID-19, (iv) discusses ethical issues in such clinical trials and (v) presents challenges associated with the use of oral antivirals in clinical practice. Oral COVID-19 antivirals represent a part of the strategy to adapt to long-term co-existence with SARS-CoV-2 in a manner that prevents healthcare from being overwhelmed. It is pivotal to ensure equal and fair global access to the currently available oral antivirals and those authorized in the future.

show abstract

Section: Pharmaceutical Targets Of Sars-cov-2mentioning

confidence: 99%

Oral antiviral treatments for COVID-19: opportunities and challenges

Rahmah

Arero²,

Jibril³

et al. 2022

Pharmacol. Rep

View full text Add to dashboard Cite

show abstract

“… 67 , 68 Therefore, inhibition of Furin may potentially suppress virus infection by twofold, via restraining viral entry and enhancing the immune response for viral clearance. 33 …”

Section: Potential Pathogenic Targets Of Sars‐cov‐2 For Antiviral The...mentioning

confidence: 99%

“…The subtilisin‐like proprotein convertase, Furin, is another attractive target and its inhibitors have shown activity against multiple furin‐dependent pathogens by twofold, including Ebola virus and bird flu virus (A H5N1), via restraining viral entry and enhancing the immune response for viral clearance. 33 Furin has recently been shown to cleave the SARS‐CoV‐2 S protein, and thus Furin inhibitors could potentially be repurposed as novel drugs for COVID‐19. 297 , 298 Through structure‐based virtual screening and post‐screening biochemical assays, it was found that diminazene can effectively inhibit the activity of Furin.…”

Section: Repurposing Clinically Available Drugs and Therapies For Pat...mentioning

confidence: 99%

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Xue

Mei

Chen

et al. 2023

MedComm

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evade existing immunity, with enhanced transmission activity and higher reinfection rates that could lead to new outbreaks across the globe. The goal of viral management is to disrupt the viral life cycle as well as to relieve severe symptoms such as lung damage, cytokine storm, and organ failure. In the fight against viruses, the combination of viral genome sequencing, elucidation of the structure of viral proteins, and identifying proteins that are highly conserved across multiple coronaviruses has revealed many potential molecular targets. In addition, the time‐ and cost‐effective repurposing of preexisting antiviral drugs or approved/clinical drugs for these targets offers considerable clinical advantages for COVID‐19 patients. This review provides a comprehensive overview of various identified pathogenic targets and pathways as well as corresponding repurposed approved/clinical drugs and their potential against COVID‐19. These findings provide new insight into the discovery of novel therapeutic strategies that could be applied to the control of disease symptoms emanating from evolving SARS‐CoV‐2 variants.

show abstract

“…Other drugs that block ACE2 have been tested in clinical trials include bromhexine with or without hydroxychloroquine and valsartan ( NCT04355026 and NCT04335786, respectively). Furin inhibitors have been proved to inhibit viral entry and replication, and are further studied for their potential to be used as a therapeutic agent against SARS-CoV-2 ( Cheng et al, 2020 ; Devi et al, 2022 ).…”

Section: Therapeutic Targets Involving Viral Proteinsmentioning

confidence: 99%

Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection

et al. 2022

View full text Add to dashboard Cite

The innate immune system is the first line of host’s defense against invading pathogens. Multiple cellular sensors that detect viral components can induce innate antiviral immune responses. As a result, interferons and pro-inflammatory cytokines are produced which help in the elimination of invading viruses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to Coronaviridae family, and has a single-stranded, positive-sense RNA genome. It can infect multiple hosts; in humans, it is responsible for the novel coronavirus disease 2019 (COVID-19). Successful, timely, and appropriate detection of SARS-CoV-2 can be very important for the early generation of the immune response. Several drugs that target the innate immune receptors as well as other signaling molecules generated during the innate immune response are currently being investigated in clinical trials. In this review, we summarized the current knowledge of the mechanisms underlying host sensing and innate immune responses against SARS-CoV-2 infection, as well as the role of innate immune receptors in terms of their therapeutic potential against SARS-CoV-2. Moreover, we discussed the drugs undergoing clinical trials and the FDA approved drugs against SARS-CoV-2. This review will help in understanding the interactions between SARS-CoV-2 and innate immune receptors and thus will point towards new dimensions for the development of new therapeutics, which can be beneficial in the current pandemic.

show abstract

A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2

Cited by 20 publications

References 58 publications

Oral antiviral treatments for COVID-19: opportunities and challenges

Oral antiviral treatments for COVID-19: opportunities and challenges

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection

Contact Info

Product

Resources

About